Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation.
Leo I. Gordon(Northwestern University), HS Jacob(Palmetto Hematology Oncology), Neil E. Kay(Mayo Clinic), Steven D. Douglas(Purdue University West Lafayette), Osamu Yamada(JR Tokyo General Hospital), E F Osserman
Cited by 137
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488